share_log

HilleVax (NASDAQ:HLVX) Shares Gap Down to $21.02

Financial News Live ·  Nov 24, 2022 00:32

HilleVax, Inc. (NASDAQ:HLVX – Get Rating) gapped down before the market opened on Wednesday . The stock had previously closed at $21.02, but opened at $20.42. HilleVax shares last traded at $20.51, with a volume of 50 shares.

HilleVax Stock Up 0.1 %

The business's 50 day moving average is $19.37 and its two-hundred day moving average is $14.70. The company has a debt-to-equity ratio of 0.02, a quick ratio of 34.77 and a current ratio of 34.77.

Get HilleVax alerts:

Hedge Funds Weigh In On HilleVax

Hedge funds have recently bought and sold shares of the company. Strs Ohio acquired a new stake in HilleVax in the second quarter worth $32,000. TD Asset Management Inc. acquired a new stake in HilleVax in the second quarter worth $203,000. Frazier Life Sciences Management L.P. acquired a new stake in HilleVax in the second quarter worth $101,493,000. JPMorgan Chase & Co. acquired a new stake in HilleVax in the second quarter worth $76,000. Finally, Alps Advisors Inc. acquired a new stake in HilleVax in the second quarter worth $217,000.

HilleVax Company Profile

(Get Rating)

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

Read More

  • Get a free copy of the StockNews.com research report on HilleVax (HLVX)
  • After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
  • Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
  • The Sell-Side Caps Gains In Dick's Sporting Goods
  • Want to Get a 10% Dividend Yield, Look Here
  • Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10

Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with MarketBeat.com's FREE daily email newsletter.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment